Pacific Edge’s American dream

Pacific Edge’s American dream
The US Affordable Care Act can be tricky to navigate. (Image: Getty)
Paul McBeth
Pacific Edge has long wanted to crack the United States market, which it has seen for a long time as validating the hundreds of millions spent in developing its Cxbladder non-invasive cancer detection tool. More than 20 years since listing, after it was spun out of University of Otago research, the company has raised $297.23 million selling shares and convertible preference shares and as people exercised options to fund accumulated losses of $216.8m and counting. That’s not going to change any time soon after the company crashed...

More Markets

NZ sharemarket claws back to end the week up 0.5%
Markets Market close

NZ sharemarket claws back to end the week up 0.5%

Index rumours drive prices on two shares. 

Graham Skellern 13 Dec 2024
Staff leave Meridian after retail 'reset'
Markets

Staff leave Meridian after retail 'reset'

Expect a very different approach from Meridian in 2025, executive says.

John Anthony 13 Dec 2024
NZX, NZSA want level playing field in climate reporting
Markets

NZX, NZSA want level playing field in climate reporting

Climate reporting liabilities for company directors could soon be eased.

Greg Hurrell 13 Dec 2024
Cannasouth delisting keeps Petterson in charge
Markets

Cannasouth delisting keeps Petterson in charge

Cannasouth major shareholders pushed to end voluntary administration they had called in.

Garth Bray 13 Dec 2024